Reduced nonprotein thiols inhibit activation and function of MMP-9: Implications for chemoprevention

Free Radical Biology and Medicine

Volumn 41, Issue 8, 2006, Pages 1315-1324

  Pei, Ping ^a   Horan, Michael P ^a   Hille, Russ ^b   Hemann, Craig F ^b   Schwendeman, Steven P ^c   Mallery, Susan R ^a,d  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Cell invasion; Chemoprevention; Free radicals; Glutathione; MMPs; Nonprotein thiols; Thiolation

Indexed keywords

ACETYLCYSTEINE; ENDOSTATIN; GELATINASE; GELATINASE A; GELATINASE B; GLUTATHIONE; ORGANOMERCURY COMPOUND; PROTEIN S; THIOL DERIVATIVE;

ADULT; AGED; ARTICLE; BASEMENT MEMBRANE; CANCER CELL; CELL INVASION; CHEMICAL REACTION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE; THIOLATION;

ACETYLCYSTEINE; ANTICARCINOGENIC AGENTS; CATALYTIC DOMAIN; CELL LINE, TUMOR; CHEMOPREVENTION; ENZYME ACTIVATION; GLUTATHIONE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MODELS, MOLECULAR; NEOPLASMS; OXIDATION-REDUCTION; PHENYLMERCURIC ACETATE; PROTEIN CONFORMATION; ZINC;

EID: 33749061028     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2006.07.014     Document Type: Article

References (47)

1. Visse R., and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function and biochemistry. Circ. Res. 92 (2003) 827-839
2. Westermark J., and Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 13 (1999) 781-792
3. Blavier L., Henriet P., Imren S., and Declerck Y.A. Tissue inhibitors of matrix metalloproteinases in cancer. Ann. N.Y. Acad. Sci. 878 (1999) 108-119
4. Curran S., and Marray G.I. Matrix metalloproteinases in tumour invasion and metastasis. J. Pathol. 189 (1999) 300-308
5. Garbett E.A., Reed M.W., and Brown N.J. Proteolysis in human breast and colorectal cancer. Br. J. Cancer 81 (1999) 287-293
6. Kurahara S., Shinohara M., Ikebe T., Nakamura S., Beppu M., Hiraki A., Takeuchi H., and Shirasuna K. Expression of MMPs, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck 21 (1999) 617-638
7. Franshi A., Santucci M., Masini E., Sardi I., Paglierani M., and Gallo O. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer 95 (2002) 1902-1910
8. Jordan R.C., Macebeo-Ong M., Shiboski C.H., Dekker N., Ginzinger D.G., Wong D.T.W., and Schmidt B.L. Overexpression of matrix metalloproteinase-1 and -9 mRNA is associated with progression of oral dysplasia to cancer. Clin. Cancer Res. 10 (2004) 6460-6465
9. Van Wart H., and Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. USA 87 (1990) 5578-5582
10. Nelson K.K., and Melendez A. Mitochondrial redox control of matrix metalloproteinases. Free Radic. Biol. Med. 37 (2004) 768-784
11. Ishii Y., Ogura T., Tatemichi M., Jufisawa H., Otsuka F., and Esumi H. Induction of matrix metalloproteinase gene transcription by nitric oxide and mechanisms of MMP-1 gene induction in human melanoma cell lines. Int. J. Cancer 103 (2003) 161-168
12. Gu Z., Kaul M., Yan B., Kridel S.J., Cui J., Strongin A., Smith J.W., Liddington R.C., and Lipton A.S. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297 (2002) 1186-1190
13. Okamoto T., Akaike T., Sawa T., Miyamoto Y., van der Vliet A., and Maeda H. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathionylation via disulfide S-oxide formation. J. Biol. Chem. 276 (2001) 29596-29602
14. Marnett L.J. Oxyradicals and DNA damage. Carcinogenesis 21 (2000) 361-370
15. Wink D.A., Vodovotz Y., Laval J., Laval F., Dewhirst M.W., and Mitchell J.B. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 19 (1998) 711-721 (Franchi et al.; Cancer 2002)
16. McCord J.M., and Edeas M.A. SOD, oxidative stress and human pathologies: a brief history and a future direction. Biomed. Pharmacother. 59 (2005) 139-142
17. Albini A., Morini M., D'Agostini F., Ferrari N., Campelli F., Arena G., Noonan D.M., Pesce C., and De Flora S. Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine. Cancer Res. 61 (2001) 8171-8178
18. Cianfrocca M., Cooley T.P., Lee J.Y., Rudek M.A., Scadden D.T., Ratner L., Pluda J.M., Figg W.D., Krown S.E., and Dezube B.J. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J. Clin. Oncol. 20 (2002) 153-159
19. Maquoi E., Sounni N.E., Devy L., Olivier F., Frankenne F., Krell H.W., Grams F., Foidart J.M., and Noel A. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,3,6-trione derivative, an orally active and selective matrix metalloproteinase inhibitor. Clin. Cancer Res. 10 (2004) 4038-4047
20. Ikejiri M., Bernardo M.M., Bonfil R.D., Toth M., Chang M., Fridman R., and Mobashery S. Potent mechanism-based inhibitors for matrix metalloproteinases. J. Biol. Chem. 280 (2005) 33992-34002
21. Mallery S.R., Morse M.A., Wilson R.F., Pei P., Ness G.M., Bradburn J.E., Renner R.J., Schuller D.E., and Robertson F.M. AIDS-related Kaposi's sarcoma cells rapidly internalize endostatin, which co-localizes to tropomyosin microfilaments and inhibits cytokine-mediated migration and invasion. J. Cell. Biochem. 89 (2003) 133-143
22. Wilson R.F., Morse M.A., Pei P., Renner R.J., Schuller D.E., Robertson F.M., and Mallery S.R. Endostatin inhibits migration and invasion of head and neck cancer cells. Anticancer Res. 23 (2003) 1289-1296
23. Rinaldi A.L., Morse M.A., Fields H.W., Rothas D.A., Pei P., Rodrigo K.A., Renner R.J., and Mallery S.R. Curcumin activates the aryl hydrocarbon receptor yet significantly inhibits (-)-benzo(a)pyrene-7R-trans-7,8-dihydrodiol bioactivation in oral squamous cell carcinoma cells and oral mucosa. Cancer Res. 62 (2002) 5451-5456
24. Mallery S.R., Pei P., Landwehr D.J., Clark C.M., Bradburn J.E., Ness G.M., and Robertson F.M. Implications for oxidative and nitrosative stress in the pathogenesis of AIDS-related Kaposi's sarcoma. Carcinogenesis 25 (2004) 597-603
25. Nyberg P., Heikkila P., Sorsa T.M., Luostarinen J., Heljasvaara R., Stenman U.-H., Pihlajaniemi T., and Salo T. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. J. Biol. Chem. 278 (2003) 22404-22411
26. Chang G., Guida W.C., and Still W.C. An internal coordinate Monte-Carlo method for searching conformational space. J. Am. Chem. Soc. 111 (1989) 4379-4386
27. Jorgensen W.L., Maxwell D.S., and Tirado-Rives J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 118 (1996) 11225-11235
28. Rowsell S., Hawtin P., Minshull C.A., Jepson H., Brockbank S.M.V., Barrat D.G., Slater A.M., McPheat W.L., Waterson D., Henney A.M., and Pauptit R.A. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J. Mol. Biol. 319 (2002) 173-181
29. Frisch M.J., Trucks G.W., Schlegel H.B., Scuseria G.E., Robb M.A., Cheeseman J.R., Montgomery Jr. J.A., Vreven T., Kudin K.N., Burant J.C., Millam J.M., Iyengar S.S., Tomasi J., Barone V., Mennucci B., Cossi M., Scalmani G., Rega N., Petersson G.A., Nakatsuji H., Hada M., Ehara M., Toyota K., Fukuda R., Hasegawa J., Ishida M., Nakajima T., Honda Y., Kitao O., Nakai H., Klene M., Li X., Knox J.E., Hratchian H.P., Cross J.B., Bakken V., Adamo C., Jaramillo J., Gomperts R., Stratmann R.E., Yazyev O., Austin A.J., Cammi R., Pomelli C., Ochterski J.W., Ayala P.Y., Morokuma K., Voth G.A., Salvador P., Dannenberg J.J., Zakrzewski V.G., Dapprich S., Daniels A.D., Strain M.C., Farkas O., Malick D.K., Rabuck A.D., Raghavachari K., Foresman J.B., Ortiz J.V., Cui Q., Baboul A.G., Clifford S., Cioslowski J., Stefanov B.B., Liu G., Liashenko A., Piskorz P., Komaromi I., Martin R.L., Fox D.J., Keith T., Al-Laham M.A., Peng C.Y., Nanayakkara A., Challacombe M., Gill P.M.W., Johnson B., Chen W., Wong M.W., Gonzalez C., and Pople J.A. Gaussian 03, revision C.02 (2004), Gaussian, Wallingford, CT
30. Kleifeld O., Van Den Steen P.E., Frenkel A., Chang F., Jiang H.L., Opdenakker G., and Sagi I. Structural characterization of the catalytic active site in the latent and active natural gelatinase B from human neutrophils. J. Biol. Chem. 275 (2000) 34335-34343
31. Liekens S., De Clercq E., and Neyts J. Angiogenesis: regulators and clinical applications. Biochem. Pharmacol. 61 (2001) 253-270
32. Shackelford R.E., Heinloth A.N., Heard S., and Paules R.S. Cellular and molecular targets of protein S-glutathiolation. Antioxid. Redox Signaling 7 (2005) 940-950
33. Wolf K., Mazo I., Leung H., Engelke K., von Andrian U., Deryugina E., Strongin A., Brocker E.-B., and Friedl P. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J. Cell Biol. 160 (2003) 267-277
34. Mallery S.R., Pei P., Kang J., Zhu G., Ness G.M., and Schwendeman S.P. Sustained angiogenesis enables in vivo transplantation of mucocutaneous derived AIDS-related Kaposi's sarcoma cells in murine hosts. Carcinogenesis 21 (2000) 1647-1653
35. Mallery S.R., Shenderova A., Pei P., Begum S., Ciminieri J.R., Wilson R.F., Casto B.C., Schuller D.E., and Morse M.A. Effects of 10-hydroxycamptothecin, delivered from locally injectable poly(lactideco-glycolide) microspheres, in a murine human oral squamous cell carcinoma regression model. Anticancer Res. 21 (2001) 1713-1722
36. Mannello F., Tonti G., and Papa S. Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr. Cancer Drug Targets 5 (2005) 285-298
37. Molina J.R., Reid J.M., Erlichman C., Sloan J.A., Furth A., Safgren S.L., Lathia C.D., and Alberts S.R. A phase I and pharmacokinetic study of the selective, non-peptide inhibitor of matrix metalloproteinase BAY 12-9566 I combination with etoposide and carboplatin. Anticancer Drugs 16 (2005) 997-1002
38. Sridhar S.S., and Shaepherd F.A. Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 42 Suppl. 1 (2003) S81-S91
39. Thomas J.P., Arzoomanian R.Z., Alberti D., Marnocha R., Lee F., Friedl A., Tutsch K., Dresen A., Geiger P., Pluda J., Fogler W., Schiller J.H., and Wilding G. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 21 (2003) 223-231
40. Varde N.K., and Pack D.W. Microspheres for controlled release drug delivery. Expert Opin. Biol. Ther. 4 (2004) 35-51
41. Schwendeman S.P. Recent advances in the stabilization of proteins encapsulated in injectable PLGS delivery systems. Crit. Rev. Ther. Drug Carrier Syst. 19 (2002) 73-98
42. Mladenov M., Mirceski V., Gjorgoski I., and Jordanoski B. Bioelectrochemistry 65 (2004) 69-76
43. Tepel M., and Zidek W. N-acetylcysteine in nephrology; contrast nephrology and beyond. Curr. Opin. Nephrol. Hypertens. 13 (2004) 649-654
44. Kelly G.S. Clinical applications of N-acetylcysteine. Altern. Med. Rev. 3 (1998) 114-127
45. Elkins P.A., Ho Y.S., Smith W.W., Janson C.A., D'Alessio K.J., McQueney M.S., Cummings M.D., and Romanic A.M. Structure of the C-terminally truncated human proMMP9, a gelatin-binding matrix metalloproteinase. Acta Crystallogr. Sect. D 58 (2002) 1182-1192
46. Maseras F., and Morokuma K. IMOMM: a new integrated ab initio + molecular mechanics geometry optimization scheme of equilibrium structures and transition states. J. Comp. Chem. 16 (1995) 1170-1179
47. DeLano W.L. The PyMol molecular graphics system (2002), DeLano Sci., San Carlos, CA. http://www.pymol.org http://www.pymol.org